Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group

Abstract

A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60 mg m –2 was given first and followed by CPT-11 at a dose of 50 mg m –2 . Both drugs were given by 1-hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles. 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48%: 95% confidence interval 32–63%) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities. © 2001 Cancer Research Campaign http://www.bjcancer.com

Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer

“…To reduce toxicity, we often use the divided schedule on days 1 and 8 as previously reported (Ueoka et al, 1998(Ueoka et al, , 2001Date et al, 2002). We conducted a previous, unsuccessful dose-escalation trial of cisplatin/etoposide chemotherapy in a divided schedule with concurrent thoracic radiation therapy (Segawa et al, 2003).…”

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer

“…In a phase II study of irinotecan and cisplatin in patients with stage IIIB or IV disease, the response rate was 52% and the median survival time was 52 weeks (Masuda et al, 1998). In order to develop a more effective regimen, studies have been conducted in which the dose intensity of irinotecan and/or cisplatin has been increased (Masuda et al, 1994;Kobayashi et al, 1998;Ueoka et al, 2001), and in which various triplet-drug combination therapies using irinotecan, cisplatin, and another drug have been explored (Shinkai et al, 1994). Ifosfamide is an analogue of cyclophosphamide and shows significant activity against NSCLC (Costanza et al, 1978).…”

Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial

“…The recommended dose of irinotecan per cycle when simultaneously combined with cisplatin was only 100 mg/m 2 and was associated with a marked response rate; however, grade 3/4 neutropenia and diarrhea occurred in 70.5% and 25.0% of the patients, respectively, and one patient died of sepsis. 19,20 In the present phase II study, grade 3/4 diarrhea developed in 35% of the patients (Table 5). It thus seems impossible to further escalate the dose of irinotecan in this setting.…”